Scientific deep-dive
What Happens When You Stop Semaglutide? STEP-4 Evidence
Stopping semaglutide is not like finishing an antibiotic course: STEP-4, the STEP-1 extension, and SURMOUNT-4 (tirzepatide) show most people regain about two-thirds of the lost weight within a year. What the trial data show, why it happens, and what to consider before stopping.
Semaglutide isn't like an antibiotic. You don't take a course and stay better. Three large randomized trials — STEP-4, the STEP-1 extension, and SURMOUNT-4 for tirzepatide — have specifically measured what happens to body weight after these drugs are stopped. The numbers are unambiguous: most patients regain about two-thirds of their lost weight within a year of discontinuation. This article walks through the actual published trial data, the proposed biological mechanism, and what these findings should change about how patients and prescribers think about “a course” of GLP-1 therapy.
STEP-4: the dedicated withdrawal trial for semaglutide
The first trial designed specifically to answer the “what happens when you stop” question for semaglutide was STEP-4, published in JAMA in April 2021 by Rubino and colleagues [1]. STEP-4 was a randomized, double-blind, 68-week phase 3a trial with an unusual design: a 20-week run-in period where everyone received semaglutide (16 weeks dose escalation up to 2.4 mg weekly, plus 4 weeks at the maintenance dose), followed by a 48-week randomization where participants who had successfully reached the full 2.4 mg dose were assigned 2:1 to either continue semaglutide or switch to placebo. Both arms continued receiving the same lifestyle intervention (counseling, exercise, calorie tracking) for the entire 68 weeks.
803 participants were randomized at week 20 — 535 to continue semaglutide and 268 to placebo. Every one of them had already lost weight on semaglutide before randomization (mean weight loss during the run-in was 10.6% of starting body weight) [1]. The question was: what happens over the next 48 weeks?
The primary endpoint was percent body weight change from week 20 (the start of randomization) to week 68 (the end of the trial). Here's what STEP-4 actually measured [1]:
| Arm | Mean weight change, week 20 → week 68 |
|---|---|
| Continued semaglutide (n=535) | −7.9% |
| Switched to placebo (n=268) | +6.9% |
| Treatment difference | −14.8 percentage points (95% CI, −16.0 to −13.5; P<.001) |
Read that carefully. The patients who stayed on semaglutide continued to lose weight — an additional 7.9% over the 48-week randomization phase. The patients who stopped semaglutide regained 6.9 percentage points of body weight over the same window. Combined, the people who continued semaglutide ended the trial about 14.8 percentage points lighter than the people who stopped. That's the largest divergence ever recorded in a weight-loss withdrawal trial.
Translated into proportional terms: STEP-4 placebo participants had lost a mean 10.6% during the run-in, then regained 6.9 points of body weight over the next 48 weeks. That's approximately 65% of the weight they had lost — gone within ~11 months of stopping the drug [1].
STEP-1 extension: what happens over a full year of discontinuation
STEP-4 measured 48 weeks post-randomization. The follow-up question — what happens after a full calendar year off the drug — was answered by a separate analysis of the STEP-1 cohort, published in Diabetes, Obesity and Metabolism in 2022 by Wilding et al. [3].
The STEP-1 extension followed 327 participants from the original STEP-1 trial [2]. In the original trial, semaglutide produced a mean weight loss of 17.3% (SD 9.3%) over 68 weeks of active treatment, versus 2.4% (SD 6.1%) on placebo [2]. After the active treatment phase ended at week 68, semaglutide was discontinued — the extension simply tracked what happened next.
By week 120 (one full year after the last semaglutide dose), participants who had been on semaglutide had regained 11.6 percentage points of weight. Their net retention from baseline had dropped from 17.3% loss to just 5.6% loss [3]. That's approximately 67% of the weight loss reversed within one year of discontinuation.
Important note for anyone seeing the “two-thirds regain” figure cited in the lay press: it comes from the STEP-1 extension [3], NOT from STEP-4 [1] as it's often misattributed. The two trials measured different things. STEP-4 measured a 48-week withdrawal divergence; the STEP-1 extension measured the full 52-week post-discontinuation trajectory. Both arrive at roughly the same answer (~64–67% regain), but the citation matters.
SURMOUNT-4: the same story for tirzepatide
Tirzepatide (the dual GIP/GLP-1 agonist sold as Zepbound for weight loss and Mounjaro for type 2 diabetes) is a meaningfully more effective drug than semaglutide on the primary efficacy endpoint, but the withdrawal pattern looks essentially the same. SURMOUNT-4, published in JAMA in 2024 by Aronne and colleagues [4], enrolled 783 adults in a 36-week open-label tirzepatide lead-in (mean weight loss 20.9%), then randomized 670 of them 1:1 to continue tirzepatide or switch to placebo for another 52 weeks. For the tirzepatide-specific detail — who regains most, cardiometabolic reversal, and the 5 mg step-down trial — see weight regain after stopping tirzepatide.
| Arm | Mean weight change, week 36 → week 88 |
|---|---|
| Continued tirzepatide (n=335) | −5.5% |
| Switched to placebo (n=335) | +14.0% |
| Treatment difference | −19.4 percentage points |
SURMOUNT-4 also reported that only 16.6% of the placebo-switched arm maintained at least 80% of their lead-in weight loss at week 88, versus 89.5% of those who continued tirzepatide [4]. That's a stronger regain signal than STEP-4 produced for semaglutide, possibly because tirzepatide's deeper appetite suppression creates a larger gap between the on-drug and off-drug homeostatic set point.
Magnitude comparison
STEP-4 (semaglutide) and SURMOUNT-4 (tirzepatide) randomized continue-vs-stop magnitudes — continuing on the maintenance dose produced additional loss while switching to placebo reversed most of the prior loss within ~1 year.[1][3][4]
- Semaglutide continued (STEP-1 ext., 120 wk)17.3 % TBWLCumulative loss with continuous treatment
- Semaglutide stopped (STEP-1 ext., 120 wk)5.6 % TBWL retained~67% of lost weight regained within 12 months
- Tirzepatide continued (SURMOUNT-4, 88 wk)25.3 % TBWLCumulative loss with continuous treatment
- Tirzepatide stopped (SURMOUNT-4, 88 wk)9.9 % TBWL retained+14.0 pts regained over 52 wk off-drug
Why the regain happens: the mechanism
GLP-1 receptor agonists modulate appetite circuits in the arcuate nucleus of the hypothalamus, including the POMC/CART satiety neurons and the NPY/AgRP hunger neurons (well-established neuroendocrine literature). The net effect is a sustained downward shift in the body's appetite set point — patients feel full faster, stop thinking about food between meals, and spontaneously eat less without willpower mediation.
When the drug is withdrawn, two things happen at once:
- The central appetite suppression dissipates as the drug is cleared. Semaglutide has a half-life of roughly one week, so hunger and food preoccupation return over the weeks following the last dose.
- Compensatory hormonal signals that regulate long-term energy balance — including ghrelin (the appetite-stimulating gut hormone) and leptin (the satiety hormone secreted by fat tissue) — adjust as fat stores rebuild, and the homeostatic system pulls weight back toward its pre-treatment set point. This defended-set-point physiology is well described in the obesity literature and is not specific to GLP-1s.
The clinical implication is uncomfortable but unambiguous: for most patients, GLP-1 weight loss is not a cure — it's a disease management strategy that requires ongoing therapy to maintain the benefit. This is exactly why the FDA-approved Wegovy indication explicitly states the drug is for weight reduction and weight maintenance, with the implication that maintenance therapy is expected to be long-term.
What this means if you're considering stopping
If you're currently on semaglutide or tirzepatide and thinking about stopping — for cost reasons, side effects, or because you've hit your target weight — the trial data is clear about what to expect. Most patients in randomized trials regained the majority of their weight within 12 months of discontinuation, even with continued lifestyle intervention.
That doesn't mean stopping is wrong. It means three things:
- Plan for the long term. If you're budgeting for compounded GLP-1 therapy, budget for years, not months. Our savings calculator shows the real out-of-pocket cost over a multi-year window.
- Tapering is poorly studied. The trials measured abrupt discontinuation, not gradual dose reduction. There is some clinical experience suggesting that stretching dosing intervals (e.g., moving from weekly to every 10-14 days) can help maintain weight loss at lower drug exposure, but the rigorous trial data isn't there yet. Our practical guide to tapering off a GLP-1 safely and our semaglutide microdosing evidence guide walk through what is and isn't known about lower-dose maintenance strategies.
- Cost matters more than usual. Because long-term therapy is the expectation, the per-month price gap between providers compounds dramatically over time. Our pricing index and 16-month price movement investigation show how the market has been moving — and how to find the cheapest legitimate provider available in your state.
The bottom line
Three peer-reviewed randomized trials have specifically measured what happens after GLP-1 weight loss medications are stopped. STEP-4 [1], the STEP-1 extension [3], and SURMOUNT-4 [4] all produce the same answer: patients regain the majority of lost weight within a year of discontinuation, even with continued lifestyle intervention. The mechanism is well-described in the published literature — central appetite suppression reverses within days, and hormonal compensation recalibrates body weight toward the pre-treatment set point.
That doesn't mean these drugs don't work. It means they work in the way you'd expect any chronic disease management medication to work — when you take them, the disease (in this case, the body's defended high weight) is suppressed; when you stop, the disease returns. Patients and prescribers should plan accordingly.
Further reading
- Top semaglutide weight-loss studies (curated PubMed reading list)
- Top semaglutide side-effect questions on Reddit, answered
Our reviews
Providers that offer semaglutide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.4. Read our review of BrightmedsCompounded or brand GLP-1 bundled with TRT and peptides for menFrom$129/mocompounded
- Editorial score: 7.4. Read our review of altRXLow-cost compounded GLP-1s with brand-name Zepbound, Wegovy and Ozempic as optionsFrom$89/mocompounded
- Editorial score: 7.4. Read our review of MadeMedCompounded GLP-1 in both injection and oral formsFrom$179/mocompounded
- Editorial score: 7.3. Read our review of HealthRXFlat-price compounded GLP-1, LegitScript-certified cash-pay programFrom$165/moafter intro offercompounded
- Editorial score: 7.3. Read our review of MEDGmBrand Wegovy, Zepbound or Ozempic access alongside cheaper compounded GLP-1From$299/moafter intro offercompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PMID: 33755728.
- 2.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 3.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID: 35441470.
- 4.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
Related research
2026 Obesity Medication Guidelines: ACP, Obesity Societies and VA/DoD Compared
US guidelines from 2025–2026 rank semaglutide and tirzepatide as the preferred weight-loss medicines, support long-term use and drop the 'diet first' rule. What the ACP, TOS/OMA/OAC and VA/DoD each recommend, where they differ, and what it means for coverage.
8 min read
7-Day GLP-1 Meal Plan: A Structured Framework (Not a Recipe Card)
A structured 7-day GLP-1 meal-plan framework — daily protein, fiber, and hydration targets and a cumulative habit-by-habit structure grounded in 2026 GLP-1 nutrition research, not a fabricated recipe card.
8 min read
Air Bubbles in Your GLP-1 Pen or Syringe: Do They Matter?
A small air bubble in your Ozempic, Wegovy, Mounjaro, or Zepbound pen is normal and safe. Here's why, plus when bubbles matter for compounded syringes.
6 min read
Best Exercise on a GLP-1: Strength + Cardio Plan
You don't have to exercise on a GLP-1, but resistance training protects muscle. An evidence-based weekly strength + cardio + steps plan.
9 min read
Can You Donate Blood on a GLP-1?
Taking a GLP-1 like Ozempic or Mounjaro generally won't bar you from donating blood. What actually matters: weight, hemoglobin, hydration, feeling well.
8 min read
Can Your Genes Predict Weight Loss on Ozempic or Zepbound? The GLP-1 Genetics Evidence
A 2026 Nature study found a gene variant clearly linked to GLP-1 weight loss, worth about 0.76 kg per copy, plus genes tied to nausea. Why a DNA test can't yet tell you whether Ozempic or Zepbound will work, and what predicts response better.
7 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $69/mo (+ required membership)
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $129/mo (“starting at” price)
Get started →From $129/mo (sale price)
Get started →